TrialSignal
Clinical trial intelligence report
Evaluation of [123I] AV94 and SPECT as a Marker of Beta-amyloid Protein Deposition in Subjects With Alzheimer Disease in Comparison to Healthy Subjects
Source-linked diligence brief with registry provenance, taxonomy normalization and premium analytical context.
Generated
Jun 20, 2026
NCT ID
NCT00605059
Status
TERMINATED
Phase
PHASE1
Sponsor
Institute for Neurodegenerative Disorders
Executive brief
Investment-Ready Snapshot
The clinical trial aimed to evaluate [123I] AV94 as a potential imaging biomarker for beta-amyloid burden in Alzheimer's disease using SPECT imaging. Conducted by the Institute for Neurodegenerative Disorders, the study involved 20 Alzheimer's patients and 10 healthy controls to assess the uptake and washout of the imaging agent.
Source & freshness
Provenance
https://clinicaltrials.gov/study/NCT00605059
Indication
Alzheimer Disease
Modality
small molecule
Target
Beta-amyloid protein deposition in Alzheimer's disease
Intervention
[123I]AV94
Source record
Protocol Description
Detailed source ingestion pending.
Source record
Outcome Measures
Detailed source ingestion pending.
Source record
Eligibility
Detailed source ingestion pending.
AI analysis
Known Results And Readout Context
Detailed source ingestion pending.
IP intelligence
Patent And IP Landscape
Detailed source ingestion pending.
Source record
Contacts
Detailed source ingestion pending.